Aging-Related Comorbidity Burden Among Women and Men With or At-Risk for HIV in the US, 2008-2019

Abstract

ImportanceDespite aging-related comorbidities representing a growing threat to quality-of-life and mortality among persons with HIV (PWH), clinical guidance for comorbidity screening and prevention is lacking. Understanding comorbidity distribution and severity by sex and gender is essential to informing guidelines for promoting healthy aging in adults with HIV.ObjectiveTo assess the association of human immunodeficiency virus on the burden of aging-related comorbidities among US adults in the modern treatment era.Design, Setting, and ParticipantsThis cross-sectional analysis included data from US multisite observational cohort studies of women (Women’s Interagency HIV Study) and men (Multicenter AIDS Cohort Study) with HIV and sociodemographically comparable HIV-seronegative individuals. Participants were prospectively followed from 2008 for men and 2009 for women (when more than 80% of participants with HIV reported antiretroviral therapy use) through last observation up until March 2019, at which point outcomes were assessed. Data were analyzed from July 2020 to April 2021.ExposuresHIV, age, sex.Main Outcomes and MeasuresComorbidity burden (the number of total comorbidities out of 10 assessed) per participant; secondary outcomes included individual comorbidity prevalence. Linear regression assessed the association of HIV status, age, and sex with comorbidity burden.ResultsA total of 5929 individuals were included (median [IQR] age, 54 [46-61] years; 3238 women [55%]; 2787 Black [47%], 1153 Hispanic or other [19%], 1989 White [34%]). Overall, unadjusted mean comorbidity burden was higher among women vs men (3.4 [2.1] vs 3.2 [1.8]; P = .02). Comorbidity prevalence differed by sex for hypertension (2188 of 3238 women [68%] vs 2026 of 2691 men [75%]), psychiatric illness (1771 women [55%] vs 1565 men [58%]), dyslipidemia (1312 women [41%] vs 1728 men [64%]), liver (1093 women [34%] vs 1032 men [38%]), bone disease (1364 women [42%] vs 512 men [19%]), lung disease (1245 women [38%] vs 259 men [10%]), diabetes (763 women [24%] vs 470 men [17%]), cardiovascular (493 women [15%] vs 407 men [15%]), kidney (444 women [14%] vs 404 men [15%]) disease, and cancer (219 women [7%] vs 321 men [12%]). In an unadjusted model, the estimated mean difference in comorbidity burden among women vs men was significantly greater in every age strata among PWH: age under 40 years, 0.33 (95% CI, 0.03-0.63); ages 40 to 49 years, 0.37 (95% CI, 0.12-0.61); ages 50 to 59 years, 0.38 (95% CI, 0.20-0.56); ages 60 to 69 years, 0.66 (95% CI, 0.42-0.90); ages 70 years and older, 0.62 (95% CI, 0.07-1.17). However, the difference between sexes varied by age strata among persons without HIV: age under 40 years, 0.52 (95% CI, 0.13 to 0.92); ages 40 to 49 years, −0.07 (95% CI, −0.45 to 0.31); ages 50 to 59 years, 0.88 (95% CI, 0.62 to 1.14); ages 60 to 69 years, 1.39 (95% CI, 1.06 to 1.72); ages 70 years and older, 0.33 (95% CI, −0.53 to 1.19) (P for interaction = .001). In the covariate-adjusted model, findings were slightly attenuated but retained statistical significance.Conclusions and RelevanceIn this cross-sectional study, the overall burden of aging-related comorbidities was higher in women vs men, particularly among PWH, and the distribution of comorbidity prevalence differed by sex. Comorbidity screening and prevention strategies tailored by HIV serostatus and sex or gender may be needed.

Polypharmacy Is Associated With Slow Gait Speed and Recurrent Falls in Older People With HIV

“…Most important, we found that polypharmacy, especially hyperpolypharmacy, was associated with poor outcomes, including higher odds of slow gait speed and recurrent falls, even after adjusting for multimorbidity and other confounders. Although previous studies showed that women had higher rates of both polypharmacy and comorbidities [ 33–37 ], ours is the first to report that this association remained statistically significant after adjusting for the number of comorbidities. This suggests that the adverse effects of polypharmacy are not simply due to an accumulation of medical conditions but rather may reflect potential toxicities and other effects of numerous simultaneous medications, in addition to the effects of comorbidities.…”

A New Start with HAART: Evaluating Breast Reconstruction in the Era of Highly Active Antiretroviral Therapy

“…30 Our analysis found elevated Elixhauser comorbidity scores in HIV-positive patients, relative to HIV-negative patients, in line with previous studies that posit greater comorbidity burden in individuals, and women in particular, who live with HIV. [31][32][33] In our assessment, Elixhauser comorbidity scores of three or fewer were protective against complications, whereas Elixhauser scores of four or more were associated with increased odds of complications. Likewise, Elixhauser scores above one were correlated with elevated odds of revision.…”

Sex and HIV Differences in Preserved Ratio Impaired Spirometry (PRISm) Among Ugandans Postpneumonia

“…To date, there have been no studies evaluating the relationship between biologic sex and the development of PRISm among women with HIV despite the association of PRISm with increased mortality [ 4–6 ]. Evidence suggests that women with HIV are at higher risk for developing aging-related comorbidities compared with men [ 36 , 37 ]; the progression and development of lung function abnormalities within this group merit further study.…”